Targeting pathogenic immune cells in rheumatoid arthritis: emerging immunotherapeutic frontiers
5 affiliations
- 1Department of Immunology, Jiangsu Key Laboratory of Laboratory Medicine, School of Clinical Medicine & Laboratory Medicine, Jiangsu University
- 2Department of Laboratory Medicine, Yizheng People’s Hospital
- 3Department of Orthopaedics, Swamy Vivekanandha Medical College Hospital and Research Institute
- 4Department of Pharmaceutics, School of Pharmacy, JSS Academy of Higher Education and Research
- 5Department of Immunology, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, School of Chemistry and Chemical Engineering, Jiangsu University
Abstract
Rheumatoid arthritis (RA) is a persistent autoimmune condition that predominantly affects the joints resulting in inflammation, pain and progressive disability. Immunological imbalance, especially the stimulation of pathogenic immune cells, including T and B cells, macrophages, amongst others, is the cause of the disease, as it is critical to the development of the disease. The limitation of traditional anti-RA medications, such as non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying anti-rheumatic drugs (DMARDs), in the treatment of the disease led to the development of more specific medicines. One of the most promising biologic agents, including monoclonal antibodies, cytokine inhibitors and cell-based therapies, are specifically targeting immune cells and inflammatory pathways in RA. This review examines these new immunotherapies, their mechanisms of action, clinical efficacy, and challenges associated with them, including resistance to treatment, safety issues, and the necessity to use personalised therapy. Also, the new immunotherapeutic approaches, which include targeting autoantibodies, gene therapy, and precision medicine, are promising new approaches that could result in more effective and personalised treatments. Finally, the review concludes with a discussion of future directions, where in combination therapies, next-generation biologics, and personalised treatment regimens are also possible and can change the way RA can be managed in the future. To preserve analytical depth, this review explicitly distinguishes established (regulatory-approved) therapies from investigational and experimental approaches and indicates the level of clinical evidence for each.
Related
- Integrative population genetics and multi-omics reveal IL15RA as a shared pathogenic hub in rheumatoid arthritis-related heart failure
- Cellular Metabolic Heterogeneity and Therapeutic Targeting in Rheumatoid Arthritis
- Joint–brain communication in rheumatoid arthritis: glial mechanisms, pain phenotypes, and translational evidence
- Histone lactylation in fibroblast-like synoviocytes drives CXCL1-mediated immune cell recruitment in rheumatoid arthritis
- Serum Calprotectin as predictor of Rheumatoid Arthritis disease severity and Mortality
BibTeX
@article{dong2026targeting,
title = {{Targeting pathogenic immune cells in rheumatoid arthritis: emerging immunotherapeutic frontiers}},
author = {Yan Dong and Xifang Xu and Sathyamoorthi S and Jindong Dai and Vijayakumar Murugesan and Selvaraj Muthusamy and Kanagaraj Rajalakshmi and Dongwei Zhu},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1895048},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1895048/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting pathogenic immune cells in rheumatoid arthritis: emerging immunotherapeutic frontiers
AU - Yan Dong
AU - Xifang Xu
AU - Sathyamoorthi S
AU - Jindong Dai
AU - Vijayakumar Murugesan
AU - Selvaraj Muthusamy
AU - Kanagaraj Rajalakshmi
AU - Dongwei Zhu
PY - 2026
DA - 2026/10/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1895048
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1895048/full
AB - Rheumatoid arthritis (RA) is a persistent autoimmune condition that predominantly affects the joints resulting in inflammation, pain and progressive disability. Immunological imbalance, especially the stimulation of pathogenic immune cells, including T and B cells, macrophages, amongst others, is the cause of the disease, as it is critical to the development of the disease. The limitation of traditional anti-RA medications, such as non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying anti-rheumatic drugs (DMARDs), in the treatment of the disease led to the development of more specific medicines. One of the most promising biologic agents, including monoclonal antibodies, cytokine inhibitors and cell-based therapies, are specifically targeting immune cells and inflammatory pathways in RA. This review examines these new immunotherapies, their mechanisms of action, clinical efficacy, and challenges associated with them, including resistance to treatment, safety issues, and the necessity to use personalised therapy. Also, the new immunotherapeutic approaches, which include targeting autoantibodies, gene therapy, and precision medicine, are promising new approaches that could result in more effective and personalised treatments. Finally, the review concludes with a discussion of future directions, where in combination therapies, next-generation biologics, and personalised treatment regimens are also possible and can change the way RA can be managed in the future. To preserve analytical depth, this review explicitly distinguishes established (regulatory-approved) therapies from investigational and experimental approaches and indicates the level of clinical evidence for each.
SN - 1664-3224
ER -